All In Biotech

Drug Trial Radar · NCT01696058

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]

Last checked: Nov 19, 2026Latest source record: Nov 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,137

Actual

Start

Sep 2012

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • TiotropiumDrug

    marketed product

  • Placebo matching OlodaterolDrug

    one dose

  • TiotropiumDrug

    marketed product

  • OlodaterolDrug

    one dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
  2. Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks

Locations

94 sites in 1 country. Site status is shown where the registry gives one.

  • 1222.52.02090 Boehringer Ingelheim Investigational Site

    Anniston, Alabama

  • 1222.52.02046 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1222.52.02014 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1222.52.02017 Boehringer Ingelheim Investigational Site

    Montgomery, Alabama

  • 1222.52.02092 Boehringer Ingelheim Investigational Site

    Anchorage, Alaska

  • 1222.52.02072 Boehringer Ingelheim Investigational Site

    Chandler, Arizona

  • 1222.52.02063 Boehringer Ingelheim Investigational Site

    Glendale, Arizona

  • 1222.52.02088 Boehringer Ingelheim Investigational Site

    Peoria, Arizona

  • 1222.52.02012 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1222.52.02006 Boehringer Ingelheim Investigational Site

    Huntington Beach, California

  • 1222.52.02031 Boehringer Ingelheim Investigational Site

    San Jose, California

  • 1222.52.02011 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 1222.52.02061 Boehringer Ingelheim Investigational Site

    Boulder, Colorado

  • 1222.52.02054 Boehringer Ingelheim Investigational Site

    Fort Collins, Colorado

  • 1222.52.02001 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 1222.52.02037 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 1222.52.02055 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1222.52.02094 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1222.52.02022 Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • 1222.52.02074 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1222.52.02016 Boehringer Ingelheim Investigational Site

    Ponte Verda, Florida

  • 1222.52.02084 Boehringer Ingelheim Investigational Site

    Saint Petersberg, Florida

  • 1222.52.02043 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1222.52.02009 Boehringer Ingelheim Investigational Site

    Blue Ridge, Georgia

  • 1222.52.02048 Boehringer Ingelheim Investigational Site

    Duluth, Georgia

  • 1222.52.02077 Boehringer Ingelheim Investigational Site

    Gainsville, Georgia

  • 1222.52.02040 Boehringer Ingelheim Investigational Site

    Rincon, Georgia

  • 1222.52.02024 Boehringer Ingelheim Investigational Site

    O'Fallon, Illinois

  • 1222.52.02002 Boehringer Ingelheim Investigational Site

    Muncie, Indiana

  • 1222.52.02008 Boehringer Ingelheim Investigational Site

    Fort Mitchell, Kentucky

  • 1222.52.02025 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1222.52.02089 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 1222.52.02005 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1222.52.02029 Boehringer Ingelheim Investigational Site

    Columbia, Maryland

  • 1222.52.02036 Boehringer Ingelheim Investigational Site

    Hollywood, Maryland

  • 1222.52.02015 Boehringer Ingelheim Investigational Site

    Townson, Maryland

  • 1222.52.02034 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 1222.52.02003 Boehringer Ingelheim Investigational Site

    Chelsea, Michigan

  • 1222.52.02020 Boehringer Ingelheim Investigational Site

    Kalamazoo, Michigan

  • 1222.52.02047 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.